Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial
- PMID: 15342830
- DOI: 10.1542/peds.2003-1104-L
Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial
Abstract
Objective: To investigate the clinical effectiveness of botulinum neurotoxin type A (BoNT) to reduce drooling in children with cerebral palsy (CP).
Methods: A controlled clinical trial was performed in which the results of single-dose BoNT injections in the submandibular glands were compared with treatment with scopolamine. Forty-five children who had CP and experienced severe drooling were enrolled. Drooling severity was measured at baseline, during application of scopolamine, and at different intervals after BoNT injections up to 24 weeks, using the Drooling Quotient (DQ), the Teacher Drooling Scale (TDS), and Visual Analog Scales (VAS).
Results: Drooling was reduced during scopolamine application as well as after BoNT injections. Compared with baseline, the mean DQ showed a significant decrease throughout the study. Greatest reductions were achieved 2 to 8 weeks after BoNT injection. No significant differences were found between scopolamine measurements and those up to 24 months after BoNT injection. Using VAS, parents recorded the effect on drooling in which significant differences were found between baseline VAS score and all follow-up assessments. According to our definition of "success to therapy," demanding a 2-point decrease on the TDS, 61.5% of patients responded to BoNT injections. Analysis of the DQ demonstrated a response rate of 53% of the patients to scopolamine and 48.7% to BoNT until 24 weeks after BoNT injections, the actual duration of this study. As a reaction to scopolamine, 71.1% of the patients had moderate to severe side effects. Only nonsevere, incidental side effects were reported after BoNT injections.
Conclusions: During scopolamine application as well as after intraglandular BoNT injections, a clinically relevant reduction in drooling was achieved in children with CP, demonstrating maximum effect 2 to 8 weeks after injections. This is the first controlled clinical trial that confirmed a significant effect of BoNT injections in the treatment of drooling. General anesthesia was needed for all children. BoNT injections show fewer and less serious side effects than transdermal scopolamine treatment.
Similar articles
-
Efficacy and duration of botulinum toxin treatment for drooling in 131 children.Arch Otolaryngol Head Neck Surg. 2010 Sep;136(9):873-7. doi: 10.1001/archoto.2010.147. Arch Otolaryngol Head Neck Surg. 2010. PMID: 20855679
-
Parotid and submandibular botulinum toxin A injections for sialorrhoea in children with cerebral palsy.Dev Med Child Neurol. 2006 Nov;48(11):883-7. doi: 10.1017/S0012162206001939. Dev Med Child Neurol. 2006. PMID: 17044954 Clinical Trial.
-
Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders.Dev Med Child Neurol. 2008 Feb;50(2):123-8. doi: 10.1111/j.1469-8749.2007.02010.x. Dev Med Child Neurol. 2008. PMID: 18201301 Clinical Trial.
-
Botulinum toxin A in the treatment of sialorrhea.Ann Pharmacother. 2007 Jan;41(1):79-85. doi: 10.1345/aph.1H381. Epub 2006 Dec 26. Ann Pharmacother. 2007. PMID: 17190848 Review.
-
[Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].Wien Klin Wochenschr. 2001;113 Suppl 4:20-4. Wien Klin Wochenschr. 2001. PMID: 15506048 Review. German.
Cited by
-
Awareness and Management of Dysphagia in Dutch Intensive Care Units: A Nationwide Survey.Dysphagia. 2019 Apr;34(2):220-228. doi: 10.1007/s00455-018-9930-7. Epub 2018 Aug 1. Dysphagia. 2019. PMID: 30069599
-
An evaluation of predictors for success of two-duct ligation for drooling in neurodisabilities.J Neurol. 2020 May;267(5):1508-1515. doi: 10.1007/s00415-020-09735-1. Epub 2020 Feb 6. J Neurol. 2020. PMID: 32025794 Free PMC article.
-
Respiratory Care Considerations for Children with Medical Complexity.Children (Basel). 2017 May 19;4(5):41. doi: 10.3390/children4050041. Children (Basel). 2017. PMID: 28534851 Free PMC article. Review.
-
Does Botulinum neurotoxin type A treatment for sialorrhea change oral health?Clin Oral Investig. 2017 Apr;21(3):795-800. doi: 10.1007/s00784-016-1826-z. Epub 2016 Apr 26. Clin Oral Investig. 2017. PMID: 27114092
-
Efficacy of scopolamine transdermal patch in children with sialorrhea in a pediatric tertiary care hospital.BMC Pediatr. 2020 Sep 17;20(1):437. doi: 10.1186/s12887-020-02336-x. BMC Pediatr. 2020. PMID: 32943036 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous